The influence of biological sex and sex hormones on bile acid synthesis and cholesterol homeostasis

• Published in: Biology of sex differences 2019-11, Vol.10 (1), p.52-52, Article 52
• Main Authors: Phelps, Taylor, Snyder, Erin, Rodriguez, Erin, Child, Hailey, Harvey, Pamela
• Format: Article
• Language: English
• Subjects: Acids; Animals; Anticholesteremic agents; Antilipemic agents; Arteriosclerosis; Atherosclerosis; Bile; Bile acids; Bile Acids and Salts - biosynthesis; Blood lipids; Cardiovascular diseases; Cerebral infarction; Cholesterol; Cholesterol - metabolism; Cytochrome; Cytochrome P450; Death; Deoxycholic acid; Development and progression; Diabetes mellitus; Enzymes; Estrogen; Estrogens; Fatty liver; Gender differences; Genes; Gonadal Steroid Hormones - metabolism; Health aspects; Heart; Heart attack; Homeostasis; Hormones; Humans; Lipids; Liver; Liver diseases; Localization; Mortality; Mutation; Myocardial infarction; Nuclear receptors; Pathology; Phenols (Class of compounds); Physiological aspects; Proteins; Review; Roles; Serum lipids; Sex Characteristics; Sex hormones; Statins; Sterols; Sudden cardiac death
• ISSN: 2042-6410; 2042-6410
• DOI: 10.1186/s13293-019-0265-3

Obesity and elevated serum lipids are associated with a threefold increase in the risk of developing atherosclerosis, a condition that underlies stroke, myocardial infarction, and sudden cardiac death. Strategies that aim to reduce serum cholesterol through modulation of liver enzymes have been successful in decreasing the risk of developing atherosclerosis and reducing mortality. Statins, which inhibit cholesterol biosynthesis in the liver, are considered among the most successful compounds developed for the treatment of cardiovascular disease. However, recent debate surrounding their effectiveness and safety prompts consideration of alternative cholesterol-lowering therapies, including increasing cholesterol catabolism through bile acid (BA) synthesis. Targeting the enzymes that convert cholesterol to BAs represents a promising alternative to other cholesterol-lowering approaches that treat atherosclerosis as well as fatty liver diseases and diabetes mellitus. Compounds that modify the activity of these pathways have been developed; however, there remains a lack of consideration of biological sex. This is necessary in light of strong evidence for sexual dimorphisms not only in the incidence and progression of the diseases they influence but also in the expression and activity of the proteins affected and in the manner in which men and women respond to drugs that modify lipid handling in the liver. A thorough understanding of the enzymes involved in cholesterol catabolism and modulation by biological sex is necessary to maximize their therapeutic potential.